Document Detail

Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT.
MedLine Citation:
PMID:  19029961     Owner:  NLM     Status:  MEDLINE    
The underlying mechanism of high-dose therapy (HDT)-related oral mucositis (OM) may be partly mediated by alterations in the normal salivary composition. This study evaluated salivary antioxidant and immunological capacities observed in myeloma patients suffering from HDT-related OM, and assessed potential contribution of these factors to OM development. Twenty-five consecutive myeloma patients treated with melphalan 200 mg/m(2) followed by autologous SCT were enrolled. Patients underwent a daily assessment for OM, and salivary samples were collected on days -3 and +7 of transplantation and analyzed for secretory IgA and antioxidant capacity. The degree of mucosal damage was assessed by measuring the salivary carbonyl and albumin (Alb) levels. OM, reported in 96% of patients, appeared to be most severe on 8 day after transplantation (range: +2 to +14). Clinical mucositis was associated with significant reduction in salivary secretory IgA (54%; P=0.05), and antioxidant activity, measured by total antioxidant status (40%; P=0.0004), antioxidant capacity (ImAnOx) (23%; P=0.002) and uric acid level (51%; P=0.006). The increase found in salivary Alb (119%; P=0.024) and carbonyl (28%; P=0.047) levels, indicates mucosal and oxidative damage, respectively. These salivary changes might enhance mucositis development and symptoms. Therapeutic interventions, enhancing antioxidative and immunological activities need to be investigated.
I Avivi; S Avraham; M Koren-Michowitz; T Zuckerman; A Aviv; Y Ofran; N Benyamini; A Nagler; J M Rowe; R M Nagler
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2008-11-24
Journal Detail:
Title:  Bone marrow transplantation     Volume:  43     ISSN:  1476-5365     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-28     Completed Date:  2009-08-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  801-6     Citation Subset:  IM    
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albumins / analysis
Antineoplastic Agents / administration & dosage,  adverse effects*
Antioxidants / analysis
Hematopoietic Stem Cell Transplantation*
Immunoglobulin A / analysis
Melphalan / administration & dosage,  adverse effects
Middle Aged
Mouth / pathology*
Mucositis / chemically induced*,  etiology
Multiple Myeloma / complications*,  therapy
Oxidative Stress
Saliva / chemistry*
Transplantation, Autologous
Reg. No./Substance:
0/Albumins; 0/Antineoplastic Agents; 0/Antioxidants; 0/Immunoglobulin A; 148-82-3/Melphalan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reflecting on 25 years with MYC.
Next Document:  Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferati...